

In the matter of the Canadian Anti-Doping Program;

And the matter of an anti-doping rule violation by Thane Hutt asserted by the Canadian Centre for Ethics in Sport;

File outcome summary

Summary

1. The Canadian Centre for Ethics in Sport (CCES) conducted an In-Competition Sample collection session on May 5, 2024, in Moncton, NB.
2. Thane Hutt (“the Athlete”) was selected for Doping Control. The Sample provided by the Athlete on May 5, 2024, returned an Adverse Analytical Finding (AAF) for Dehydrochloromethyltestosterone (“DHCMT”), GW501516 metabolites (sulfone and sulfoxide) (“GW501516”), and Amfetamine, all Prohibited Substances.
3. Prior to notifying the Athlete of the AAF, the CCES conducted an Out-of-Competition Sample collection session with the Athlete on June 13, 2024, in Fredericton, NB. The Athlete refused to provide a Sample.
4. Following receipt of the CCES’s Notice of Charge asserting an anti-doping rule violation (ADRV) for the presence and Use of the Prohibited Substances, as well as for refusing to submit to Sample collection, the Athlete signed an Early Admission and Acceptance of Sanction Form, thereby admitting the ADRV, waiving his right to a hearing and accepting all applicable Consequences.

Jurisdiction

5. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada. The CCES also maintains and implements the Canadian Anti-Doping Program (CADP), including providing anti-doping services to national Sport Organizations and their members.
6. As Canada’s National Anti-Doping Organization, the CCES is compliant the World Anti-Doping Code (“the Code”) and its mandatory International Standards. The CCES has implemented the Code and the International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
7. The Athlete is a member of and participates in the activities of the Canadian Powerlifting Union (CPU). According to CADP Rule 1.3, the CADP provisions apply to all members of, and Participants in activities of Sport Organizations adopting it. The CADP was issued for adoption by Canadian Sport Organizations on October 26, 2020. The CPU adopted the CADP on October 29, 2020. Therefore, as a Participant in CPU activities, the Athlete is subject to the CADP.

Doping Control

8. On May 5, 2024, the CCES conducted an In-Competition Sample collection session, in Moncton, NB. Testing was conducted as part of the CCES’s domestic test distribution plan, all pursuant to the CADP.

9. The Athlete was notified that he had been selected for Doping Control and, together with the Doping Control Officer from the CCES, completed the Sample collection process. The Athlete's Sample code number was 7175309.
10. On May 7, 2024, the Athlete's Sample was received for analysis by the INRS Centre Armand-Frappier Santé Biotechnologie ("the INRS"), a World Anti-Doping Agency (WADA) accredited laboratory in Laval, Quebec.
11. On June 13, 2024, after being notified for Doping Control and reminded of the requirement to comply with Sample collection, and that a failure to comply or refusal to provide a Sample may result in an anti-doping rule violation (ADRV), the Athlete refused to provide a urine Sample and completed a Potential Failure to Comply Form, which was received by the CCES on June 14, 2024.

Results Management

12. The AAF was reported by the INRS on May 27, 2024. The Certificate of Analysis indicated the presence of DHCMT, GW501516, and Amfetamine.
13. DHCMT, GW501516, and Amfetamine are classified as non-Specified Substances on the World Anti-Doping Agency's (WADA) 2024 Prohibited List.
14. Following receipt of the Potential Failure to Comply Form on June 14, 2024, the CCES commenced an initial review into the Athlete's AAF and failure to submit to Sample collection and/or refusal to provide a Sample.
15. As the Athlete had not been notified of the AAF for his Sample collected on May 5, 2024, prior to the potential failure to submit and/or refusal violation, all potential violations constitute one single first violation, and the sanction imposed shall be based on the violation that carries the more severe sanction in accordance with CADP Rule 10.9.3.1.
16. The CCES issued a notification of potential ADRVs on July 16, 2024.
17. On July 17, 2024, the Athlete responded to the CCES's Notification letter with their explanation.
18. On August 2, 2024, the CCES formally issued a Notice of Charge asserting an ADRV against the Athlete for the presence and Use of Prohibited Substances, as well as for failing to submit to Sample collection and/or refusing to provide a Sample.
19. In accordance with CADP Rules 10.2.1.1 and 10.3.1, the sanction for an ADRV involving the presence and Use of non-Specified Substances is a four (4) year period of Ineligibility, and the sanction for failure to submit to Sample collection and/or refusing to provide a Sample is also a four (4) year period of Ineligibility.
20. For the reasons mentioned above, the sanction imposed shall be based on the violation that carries the more severe sanction in accordance with CADP Rule 10.9.3.1.
21. After assessing the circumstances of this case, the CCES considered there were Aggravating Circumstances, given the Athlete's Use of multiple Prohibited Substances and their refusal to

provide a Sample, which justified an additional two (2) year period of Ineligibility pursuant to CADP Rule 10.4.

22. The CCES therefore asserted a six (6) year period of Ineligibility, in addition to all applicable Consequences in its Notice of Charge on August 2, 2024.

Confirmation of Violation and Sanction

23. In accordance with CADP Rule 10.8.1, the CCES informed the Athlete on August 2, 2024, that should the Athlete exercise their option to sign the Early Admission and Acceptance of Sanction Form, the Athlete would receive a one (1) year reduction of the six (6) year period of Ineligibility asserted by the CCES.

24. On August 18, 2024, the Athlete signed and submitted the Early Admission and Acceptance of Sanction Form to the CCES. Accordingly, effective August 18, 2024, an ADRV has been confirmed against the Athlete for the presence and Use of the identified Prohibited Substances and the failure to submit to Sample collection and/or refusal to provide a Sample. In accordance with CADP Rules 7.4.1, 10.2.1.1, 10.4, 10.8.1, 10.9.3.1 and 10.13.2.1, the sanction for this violation is a five (5) year period of Ineligibility which commenced on July 16, 2024, the date the Athlete was provisionally suspended, and concludes on July 15, 2029.

25. Further, in accordance with CADP Rules 9, 10.1 and 10.10, any competitive results obtained by the Athlete, including and from the date of the May 5, 2024, Sample collection, shall be Disqualified.

26. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 9th day of September 2024.



Kevin Bean
Executive Director, Sport Integrity
CCES